 ROCKVILLE, Md., Sept. 27, 2021 PRNewswire -- Interim data for Cohort 1 with six months of follow-up from the RGX-314 Phase II trial for the treatment of wet AMD AAVIATE to be presented REGENXBIO to host conference call and webcast to review the interim data from the AAVIATE trial on Friday, October 1, 2021, at 5:00 p.m. 